The United States FDA Approved Bristol Myers Squibb’s COBENFY™ - A First-In-Class Muscarinic Agonist for Schizophrenia in Adults

Bristol-Myers Squibb COBENFY™ Approval Bristol Myers Squibb ( BMY ) announced that the U.S. FDA has approved COBENFY™ (xanomeline and trospium chloride) for schizophrenia in adults.  Schizophrenia is...